Pages that link to "Q68823555"

The following pages link to Fixed-dose fluoxetine therapy for depression (Q68823555):

Displaying 19 items.

• Assessing and interpreting treatment effects in longitudinal clinical trials with missing data (Q30787487) (← links)
• Duloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisons (Q33251729) (← links)
• Sertraline. A pharmacoeconomic evaluation of its use in depression (Q33583619) (← links)
• Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice (Q33738090) (← links)
• Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review (Q34240696) (← links)
• Antidepressant drugs and the emergence of suicidal tendencies (Q34361870) (← links)
• Comparative efficacy and risk of harms of immediate- versus extended-release second-generation antidepressants: a systematic review with network meta-analysis (Q35162633) (← links)
• Fluoxetine: a review of receptor and functional effects and their clinical implications. (Q35228372) (← links)
• Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review (Q36114397) (← links)
• Dose-response relationship of recent antidepressants in the short-term treatment of depression. (Q36255130) (← links)
• Does differential drop-out explain the influence of study design on antidepressant response? A meta-analysis (Q36650741) (← links)
• Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials (Q37202188) (← links)
• Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout (Q37503551) (← links)
• Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis (Q37610143) (← links)
• Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness (Q39461139) (← links)
• Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism (Q41382531) (← links)
• Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. (Q51912832) (← links)
• Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors (Q56864512) (← links)
• Does fluoxetine have a therapeutic window? (Q68311440) (← links)